SCHEMBL6163154

SCHEMBL6163154

COc1ccc(-c2cc(C(=O)N3CCCC3CO)c3ccccc3n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.67
POLB P06746 1/20 0.67
TDP1 Q9NUW8 1/20 0.66
TRPV1 Q8NER1 2/20 0.61
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 3/20 0.60
LMNA P02545 2/20 0.60
GAA P10253 1/20 0.60
MAPT P10636 2/20 0.60
HPGD P15428 2/20 0.60
KMT2A Q03164 2/20 0.60
TP53 P04637 2/20 0.60
MAPK1 P28482 2/20 0.60
HSD17B10 Q99714 2/20 0.60
MEN1 O00255 1/20 0.60
CASP1 P29466 1/20 0.60
CASP7 P55210 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
BCHE P06276 1/20 0.60
PREP P48147 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163856 1.00 RAB9A (0.67) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6165000 1.00 RAB9A (0.67) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6166721 0.91 TRPV1 (0.61) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6164732 0.91 TRPV1 (0.61) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6164640 0.91 TRPV1 (0.61) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6162631 0.91 TDP1 (0.59) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6163720 0.91 TDP1 (0.59) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6166256 0.91 TDP1 (0.59) RAB9APOLBTDP1TRPV1KDM4E
SCHEMBL6161963 0.90 TRPV1 (0.57) RAB9APOLBTRPV1KDM4EALDH1A1
SCHEMBL6166073 0.90 TRPV1 (0.57) RAB9APOLBTRPV1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RAB9A 628/4885POLB 1324/4885TDP1 745/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RAB9A 628/4885POLB 1324/4885TDP1 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.